Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review
Xiang Zou
1
,
Xi-Yu Tang
1
,
Zhong Yuan Qu
2
,
Zhiwei Sun Zhiwei Sun
2
,
CHEN-FENG JI
1
,
Yan-jie Li
3
,
Shoudong Guo
1, 3
Publication type: Journal Article
Publication date: 2022-03-01
scimago Q1
wos Q1
SJR: 1.285
CiteScore: 10.3
Impact factor: 8.5
ISSN: 01418130, 18790003
PubMed ID:
35074329
Biochemistry
Molecular Biology
General Medicine
Structural Biology
Abstract
Platelet-derived growth factors (PDGFs) and PDGF receptors (PDGFRs) are expressed in a variety of tumors. Activation of the PDGF/PDGFR signaling pathway is associated with cancer proliferation, metastasis, invasion, and angiogenesis through modulating multiple downstream pathways, including phosphatidylinositol 3 kinase/protein kinase B pathway and mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Therefore, targeting PDGF/PDGFR signaling pathway has been demonstrated to be an effective strategy for cancer therapy, and accordingly, some great progress has been made in this field in the past few decades. This review will focus on the PDGF isoforms and their binding with the related PDGFRs, the PDGF/PDGFR signaling and regulation, and especially present strategies and inhibitors developed for cancer therapy, and the related clinical benefits and side effects.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
6
7
8
9
|
|
|
International Journal of Molecular Sciences
9 publications, 5.52%
|
|
|
Scientific Reports
7 publications, 4.29%
|
|
|
Frontiers in Oncology
5 publications, 3.07%
|
|
|
Signal Transduction and Targeted Therapy
5 publications, 3.07%
|
|
|
Frontiers in Immunology
4 publications, 2.45%
|
|
|
Cancers
4 publications, 2.45%
|
|
|
Journal of Translational Medicine
4 publications, 2.45%
|
|
|
Biochemical and Biophysical Research Communications
3 publications, 1.84%
|
|
|
Biomedicine and Pharmacotherapy
3 publications, 1.84%
|
|
|
Cancer Cell International
3 publications, 1.84%
|
|
|
Frontiers in Pharmacology
3 publications, 1.84%
|
|
|
International Journal of Biological Macromolecules
2 publications, 1.23%
|
|
|
MedComm
2 publications, 1.23%
|
|
|
Heliyon
2 publications, 1.23%
|
|
|
Cancer Science
2 publications, 1.23%
|
|
|
Biochimica et Biophysica Acta - Molecular Basis of Disease
2 publications, 1.23%
|
|
|
Antioxidants
2 publications, 1.23%
|
|
|
Journal of Materials Chemistry B
2 publications, 1.23%
|
|
|
Biomedicines
2 publications, 1.23%
|
|
|
Neuro-Oncology
2 publications, 1.23%
|
|
|
Journal of Hematology and Oncology
2 publications, 1.23%
|
|
|
Genes and Diseases
2 publications, 1.23%
|
|
|
Hereditas
2 publications, 1.23%
|
|
|
Cancer Drug Discovery and Development
2 publications, 1.23%
|
|
|
World Journal of Gastrointestinal Oncology
2 publications, 1.23%
|
|
|
Journal of Nanobiotechnology
1 publication, 0.61%
|
|
|
Computers in Biology and Medicine
1 publication, 0.61%
|
|
|
Chemico-Biological Interactions
1 publication, 0.61%
|
|
|
Materials Today Bio
1 publication, 0.61%
|
|
|
1
2
3
4
5
6
7
8
9
|
Publishers
|
5
10
15
20
25
30
35
40
45
|
|
|
Springer Nature
41 publications, 25.15%
|
|
|
Elsevier
40 publications, 24.54%
|
|
|
MDPI
24 publications, 14.72%
|
|
|
Frontiers Media S.A.
17 publications, 10.43%
|
|
|
Wiley
10 publications, 6.13%
|
|
|
Oxford University Press
6 publications, 3.68%
|
|
|
Cold Spring Harbor Laboratory
4 publications, 2.45%
|
|
|
Taylor & Francis
4 publications, 2.45%
|
|
|
Baishideng Publishing Group
3 publications, 1.84%
|
|
|
Royal Society of Chemistry (RSC)
2 publications, 1.23%
|
|
|
Georg Thieme Verlag KG
2 publications, 1.23%
|
|
|
Hindawi Limited
1 publication, 0.61%
|
|
|
Public Library of Science (PLoS)
1 publication, 0.61%
|
|
|
PeerJ
1 publication, 0.61%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.61%
|
|
|
SAGE
1 publication, 0.61%
|
|
|
Spandidos Publications
1 publication, 0.61%
|
|
|
OAE Publishing Inc.
1 publication, 0.61%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 0.61%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.61%
|
|
|
CSIRO Publishing
1 publication, 0.61%
|
|
|
5
10
15
20
25
30
35
40
45
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
163
Total citations:
163
Citations from 2024:
128
(78.52%)
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Zou X. et al. Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review // International Journal of Biological Macromolecules. 2022. Vol. 202. pp. 539-557.
GOST all authors (up to 50)
Copy
Zou X., Tang X., Qu Z. Y., Zhiwei Sun Z. S., JI C., Li Y., Guo S. Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review // International Journal of Biological Macromolecules. 2022. Vol. 202. pp. 539-557.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.ijbiomac.2022.01.113
UR - https://doi.org/10.1016/j.ijbiomac.2022.01.113
TI - Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review
T2 - International Journal of Biological Macromolecules
AU - Zou, Xiang
AU - Tang, Xi-Yu
AU - Qu, Zhong Yuan
AU - Zhiwei Sun, Zhiwei Sun
AU - JI, CHEN-FENG
AU - Li, Yan-jie
AU - Guo, Shoudong
PY - 2022
DA - 2022/03/01
PB - Elsevier
SP - 539-557
VL - 202
PMID - 35074329
SN - 0141-8130
SN - 1879-0003
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2022_Zou,
author = {Xiang Zou and Xi-Yu Tang and Zhong Yuan Qu and Zhiwei Sun Zhiwei Sun and CHEN-FENG JI and Yan-jie Li and Shoudong Guo},
title = {Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review},
journal = {International Journal of Biological Macromolecules},
year = {2022},
volume = {202},
publisher = {Elsevier},
month = {mar},
url = {https://doi.org/10.1016/j.ijbiomac.2022.01.113},
pages = {539--557},
doi = {10.1016/j.ijbiomac.2022.01.113}
}